CAMBRIDGE, Mass.–(BUSINESS WIRE)–Digital Therapeutics Alliance (“DTA” or “Alliance”), a global non-profit trade association of industry leaders and stakeholders with the mission of broadening the understanding and adoption of digital therapeutics (DTx) into healthcare, today announced the election of Everett Crosland, Chief Commercial Officer, Cognito Therapeutics to its Board of Directors.
“Everett brings a wealth of knowledge about the DTx industry, particularly on commercialization, reimbursement, patient services, and government affairs,” said Andy Molnar, CEO, Digital Therapeutics Alliance. “His understanding of the need for commercial acceleration and alignment with members across all regions make him well-positioned to help us reach our strategic goals.”
“I look forward to working with Andy and the rest of the DTA team, members and Board of Directors to advance next-generation digital therapeutics,” said Everett Crosland, Chief Commercial Officer, Cognito Therapeutics and DTA Board Member. “At Cognito, we’re advancing the first disease-modifying digital therapeutic for Alzheimer’s disease, a clinically and financially devastating disease, where new therapies are desperately needed for patients.”
At Cognito, Everett leads key commercialization activities in conjunction with the leadership team. Before joining Cognito, Everett was Chief Commercial Officer at AppliedVR, where he led national launch sales, marketing, and payer strategy on the first breakthrough designated virtual reality therapeutic. Prior to AppliedVR, he was VP of Market Access & Reimbursement with Pear Therapeutics, leading payer, reimbursement, and government strategy on the first breakthrough designated digital therapeutic. In past roles he has led the launch readiness and market access and reimbursement commercialization of novel infused and oral drugs, drug-device combinations, and digital therapeutics.
About Digital Therapeutics Alliance (DTA)
The Digital Therapeutics Alliance (DTA) is a global non-profit trade association of industry leaders and stakeholders with the mission of broadening the understanding and adoption of digital therapeutics into healthcare. DTA works to enable expanded access to high quality, evidence-based digital therapeutics for patients, clinicians, and payors in order to improve clinical and health economic outcomes. To learn more, please visit: www.dtxalliance.org.
About Cognito Therapeutics
Cognito Therapeutics is a pioneer in optogenetics to treat neurodegenerative diseases and improve human cognitive performance. The company has completed multiple clinical studies demonstrating its investigational therapeutic has the potential to safely slow or stop cognitive decline and loss of brain volume in Alzheimer’s disease. Cognito has received FDA Breakthrough Device Designation for the treatment of Alzheimer’s disease and expects to start pivotal studies in 2022. The company’s technology was based on pioneering optogenetics research by scientific co-founders Professors Li-Huei Tsai and Ed Boyden at MIT. Cognito Therapeutics is based in Cambridge, MA. For more information, please visit www.cognitotx.com. Follow us on Twitter at @cognitotx.